14.01.2025 • News

Alcami Announces CEO Transition

Alcami, a contract development and manufacturing organization (CDMO), recently announced the resignation of its CEO, Bill Humphries. Alcami’s Board Chair and former CEO Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations.

"On behalf of the Board, I’d like to express gratitude to Bill for his leadership over the last two years during a critical time of facilities expansion and a global supply chain realignment. He was a strong advocate for our clients and the organization benefited from his leadership. I am personally grateful for his contributions and wish him all the best in his new opportunity,” commented Patrick Walsh, Interim CEO, Alcami.

Mr. Walsh served as CEO of Alcami on two previous occasions and has served as Chairman over the last four years. In addition to his duties at Alcami, he currently serves as Chairman of ANI Pharmaceuticals, Chairman of MedPharm, and is an Operating Partner at Ampersand Capital Partners.
Patrick Walsh, Interim CEO, Alcami. © Alcami
Patrick Walsh, Interim CEO, Alcami. © Alcami

Company

Logo:

Alcami Corporation

4620 Creekstone Drive
27703 Durham
US

Company contact







Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Top-Feature

most read